Thu. 13 Jun 2024, 4:10pm ET
Benzinga
Biotech, News, General
151 subjects enrolled in various stages of loading and randomization in SOL-1 pivotal study of AXPAXLI in wet AMD as of June 7, 2024
Announces plans for SOL-R study to evaluate repeat doses of AXPAXLI in wet AMD
48-week HELIOS NPDR results show 23.1% of patients in AXPAXLI arm experienced ≥2-step DRSS improvement with no patients experiencing worsening of DRSS or vision threatening complications